Introduction
General transcription factor TFIID is composed of the TATA-binding protein (TBP) and 13-14 evolutionary conserved TBP-associated factors (TAFs) (Tora, 2002) . These factors assemble to form a large multi-protein complex comprising three large lobes around a central cavity (Leurent et al., 2004; Matangkasombut et al., 2004; Grob et al., 2006) . TAF4 is a ubiquitously expressed TFIID subunit that is also present in TFTC (Tanese et al., 1996; Mengus et al., 1997; Brand et al., 1999; Thuault et al., 2002) . TAF4 is essential in yeast and plays a general role in transcription in Caenorhabditis elegans embryos (Sanders and Weil, 2000; Walker et al., 2001) . The TAF4 family also comprises TAF4b that is required for testis and ovary function (Freiman et al., 2001; Falender et al., 2005) .
We previously characterized taf4 À/À embryonic fibroblasts where TAF4 inactivation promotes altered cell morphology and serum-independent autocrine growth accompanied by a deregulation (both positive and negative) of more than 1000 genes (Mengus et al., 2005) . Among the affected genes, are transforming growth factor (TGF)b1, b3 (for review see (Shi and Massague, 2003) and connective tissue growth factor (CTGF) that has intrinsic growth factor properties and interacts directly with TGFb1 to facilitate binding to its surface receptor enhancing the proliferative response of fibroblasts to TGFb (Abreu et al., 2002) . In addition, loss of TAF4 induces matrix metalloproteases and thrombospondin that activate latent TGFb (Yu and Stamenkovic, 2000; Annes et al., 2003) . As a consequence, taf4
À/À cells secrete high levels of active TGFb inducing a positive autoregulatory feedback loop of TGFb signalling.
We have also suggested that TAF4 may be a coactivator for the RAR (all-trans retinoic acid receptor) transcription factor (Mengus et al., 1997; Gangloff et al., 2000) as the activity of transfected RAR is strongly diminished in taf4 À/À cells (Mengus et al., 2005) . To evaluate the role of TAF4 in activation of cellular genes by RARs, we have characterized the response of taf4 lox/À and taf4 À/À cells to all-trans retinoic acid (T-RA) showing that TAF4 is required for regulation of most, but not all cellular genes. Our results also reveal that, like taf4
À/À cells, T-RA-treated taf4 lox/À cells exhibit TGFb-dependent autocrine growth. These results highlight the role of TAF4 as a cofactor for RAR in the cellular response to T-RA and reveal the genetic programme of cross talk between the T-RA and TGFb pathways that leads to deregulated cell growth.
Results

Retinoic acid response of embryonic fibroblasts
While T-RA induces differentiation in cell types such as F9 or ES cells, its effect on fibroblasts has not been characterized. After 5 days in the presence of T-RA, a significant morphological change of the taf4 lox/À cells (two independent clones 1 and 2, see Mengus et al., 2005) was observed as they lost their round regular shape to adopt a more elongated form (Supplementary Figures 1A and B) . In contrast, taf4 À/À cells already have an irregular elongated morphology due to loss of TAF4 (Mengus et al., 2005) and no further significant change was observed (Supplementary Figures 1C and D) . The change in morphology of the TAF4-expressing cells implies significant changes in gene expression.
We Supplementary Tables 1 and 2 . For clarity, some co-regulated genes are boxed in yellow. RA-TGF-b crosstalk A Fadloun et al no significant induction of ARG2, CP and ENPP3 was observed (Figure 3a, lanes 3-4) . Potent T-RA induction of MBD1 in taf4 lox/À cells was confirmed by quantitative PCR which also revealed a much smaller yet significant induction in taf4 À/À cells (Figure 3b ). Together, these results show that T-RA regulates almost 1000 genes in fibroblasts. The regulation of a small group of genes is independent of TAF4, while that of the majority requires TAF4.
RA-TGF-b crosstalk
We have previously described a taf4 À/À cell line in which we have reexpressed the conserved region II (CRII) domain of TAF4 (taf4 À/À/tg þ (Mengus et al., 2005) . Expression of this domain represses serumindependent growth and is sufficient to mediate the function of the transfected RAR. In these cells, the T-RA inducibility of only a subset of genes is observed. For example, T-RA induces expression of cellular retinoic acid binding protein 2 (CRABP2), TGFb3, thrombospondin 2 (THBS2) and CTGF, while growth arrest specific 2 (GAS2) is repressed ( Supplementary  Figures 2A and B) . In contrast, no comparable induction of MBD1 or ENPP1 is observed. Although 
A Fadloun et al the CRII domain is sufficient for RAR activity at some promoters, additional domains of TAF4 are therefore required to mediate activation at others.
Cross talk between the T-RA and TGFb pathways Analysis of T-RA-regulated genes in taf4 lox/À cells revealed that many were also induced by the loss of TAF4 (Figure 1b) . A global comparison revealed that of 408 induced by T-RA in taf4 lox/À cells, 119 were also upregulated by loss of TAF4 in taf4 À/À cells (Figure 1a  and see Supplementary Table 2) . Among these are genes previously implicated in the constitutive activation of the TGFb pathway such as TGFb1 and 3, the secreted growth factors CTGF and secreted phosphoprotein 1 (also known as osteopontin, OPN), THBS2 (thrombospondin 2), an activator of latent TGFb, as well as the VAV3 oncogene and transcription factors such as MAFF, ETS, BCL6 and KFL5 previously shown to be regulated both by loss of TAF4 and during the adaptive response to low serum (Mengus et al., 2005) .
Similarly, of the 570 T-RA downregulated genes, 259 are also downregulated by loss of TAF4 ( Figure 2a and see Supplementary Table 3 ) including the cell surface TGFb antagonist ASPN (asporin) (Kizawa et al., 2005) , GAS2 and the transcription factor HOD (homeodomain-only factor) (Chen et al., 2002) that we have previously shown to be downregulated upon adaptation to low serum (Mengus et al., 2005) . A small group of genes is also regulated in both taf4 lox/À and taf4 À/À cells by T-RA and by loss of TAF4 (Figures 1 and 2 and  Supplementary Tables 2 and 3) . We also verified whether T-RA treatment alters the expression of TAF4 and TAF4b. No changes in the mRNA levels of these genes are observed (data not shown), and the levels of the corresponding proteins are not affected by the presence of T-RA (Supplementary Figure 2D) . The convergence of the T-RA-induced and taf4 À/À transcriptomes therefore cannot be explained by a T-RAmediated repression or activation of TAF4 and TAF4b expression respectively.
The expression of several genes was also verified by RT-PCR on RNA prepared from taf4 lox/À and taf4 There is therefore a significant overlap among the genes deregulated upon loss of TAF4 and by T-RA corresponding to those involved in TGFb signalling suggesting a potential functional cross talk between the T-RA and TGFb pathways.
T-RA induces TGFb-dependent autocrine growth Deregulation of many of the above genes was associated with serum-independent autocrine growth and constitutive TGFb activation in taf4 À/À cells. Their analogous deregulation in T-RA-treated taf4 lox/À cells suggests that in turn these cells may also have altered growth properties. To test this, taf4 lox/À and taf4 À/À cells were grown in the absence of serum with or without T-RA. As previously shown (Mengus et al., 2005) , taf4 lox/À cells die in the absence of serum, whereas taf4
À/À cells survive (Figure 4a ). Strikingly however, in the presence of T-RA, the taf4 lox/À cells now exhibit serum independence ( Figure 4a ) showing that T-RA induces serum-independent autocrine growth of taf4 lox/À cells. The taf4 À/À/tg þ cells expressing the CRII domain in which only a subset of genes are induced also showed T-RA-induced serum-independent growth (Supplementary Figure 3A) .
Serum-independent growth of the taf4 lox/À cells did not require the continuous presence of T-RA. Cells treated for 30 min or 2 h with T-RA did not show serum independence, however cells treated for 24 h showed autocrine growth analogous to that of cells kept in the continuous presence of T-RA (Supplementary Figure  3B) . Thus, transient T-RA treatment is sufficient to induce the signalling pathways necessary for autocrine growth.
To test whether this was associated with TGFb signalling, T-RA-treated cells were grown for several days without serum and the conditioned medium was tested for the presence of active TGFb using a 3T3 cell line harbouring an integrated luciferase reporter gene under the control of multiple SMAD binding sites (Inman et al., 2002) . The low basal luciferase activity seen in the absence of serum was strongly stimulated by recombinant TGFb1 (Figure 4b , lanes 1 and 2). A similar high level of luciferase activity was observed using serum-free conditioned medium from T-RA-treated taf4 lox/À cells (lane 3), showing that these cells secrete significant amounts of active TGFb. Similarly, taf4 À/À and taf4 lox/À cells were grown overnight in absence of serum and then incubated for 15 min with serum-free medium containing recombinant TGFb resulting in a significant increase in the phosphorylation of SMAD2/3 (Figure 4c , lanes 1 and 3). Phosphorylation was also strongly stimulated in the presence of conditioned medium from the taf4 À/À cells (lane 2) previously shown to secrete TGFb (Mengus et al., 2005) . A similar increase was seen with the conditioned medium from T-RA-treated taf4 lox/À cells, (lane 4). These results confirm that like the taf4 À/À cells, the T-RA-treated taf4 lox/À cells secrete active TGFb.
We next determined whether the TGFb signalling was necessary for serum independence using SB431542, a selective inhibitor of this pathway (Laping et al., 2002) . The presence of this inhibitor suppresses serum independence of both the taf4 À/À and the T-RAtreated taf4 lox/À cells (Figure 4a) . A similar inhibition of T-RA-induced autocrine growth was observed using neutralizing antibodies against TGFb (data not shown). Together, these results show that T-RA-treated taf4 lox/À cells secrete active TGFb that is essential for serum-independent growth. 
Retinoic acid induces CTGF expression
We investigated the mechanism by which T-RA induces genes of the TGFb pathway. RNA was prepared from taf4 lox/À cells after 2-24 h of T-RA treatment and the induction of several target genes was verified. CTGF was rapidly and potently induced already 2 h after T-RA addition before weakening at later times (Figure 3e and Supplementary Figures 2B and C) . Similarly, ENPP1 was also rapidly induced to maximal level after 2 h. The known direct RAR target gene CRABP2 is induced after 2 h and continues to accumulate over the 24 h period. Analogous observations were made for INMT and MBD1. In contrast, upregulation of ENPP3, OPN, TGFb1 and b3 began only 4-8 h after T-RA treatment (Figure 3e and data not shown) . A similar analysis of downregulated genes confirmed that GAS2 and ASPN were both repressed by T-RA. GAS2 was rapidly repressed within 2 h, while repression of ASPN was evident only after 4 h (Figure 3e) .
Activation of THBS2 expression began after 12 h suggesting that it is a secondary response to the enhanced TGFb expression. Consistent with this idea, the activation of THBS2 expression seen upon addition of either T-RA or recombinant TGFb is blocked in the presence of SB431542 (Figure 3d ). In contrast, although autocrine activation of TGFb3 by recombinant TGFb is almost completely abolished by SB431542 (lanes 7-10), T-RA-induced TGFb3 expression shows only a mild reduction (lanes 1-6). TGFb3 expression is thus controlled by two different mechanisms, in normal conditions by a positive feedback loop, but by a distinct TGFb-independent mechanism in the presence of T-RA. The mild reduction of T-RA-induced expression seen in the presence of SB431542 may be explained by the fact that after 24 h, TGFb3 expression levels reflect not only induction by T-RA, but also increased autocrine regulation. The positive feedback control of TGFb3 expression would explain the observation that T-RA is only transiently required to initiate the pathway.
The rapid and potent activation of CTGF expression suggest that it is a direct target of RAR. We examined the CTGF promoter for the presence of potential RAR responsive elements (RAREs). At position -160 of the CTGF promoter is an evolutionary conserved direct repeat DR2 class of RARE (Figure 5a , and Supplementary Figures 4B and 7) . To verify if the RAR binds this element, we performed electrophoretic mobility shift assays (EMSA) using extracts of Cos cells transfected with retinoic acid receptor g (RARg) and retinoid X receptor a (RXRa). A retarded complex was formed using a known DR2 RARE from the CRABP2 promoter (Durand et al., 1992) (Figures 5a and b , lane 4) and strongly diminished by a polyclonal antiRARg antisera (lane 5). An analogous complex was formed using the CTGF DR2 element that was again diminished by the antisera and also by point mutations in the core 5 0 -TCA-3 0 of one of the repeats (lanes 6-9). These results identify a conserved DR2 type RARE in the CTGF proximal promoter that binds the RAR/ RXR heterodimer.
We asked whether upregulation of CTGF was sufficient to induce the TGFb pathway and autocrine growth. The taf4 lox/À cells were transfected with a CTGF expression vector, and induction of TGFb pathway genes was verified by RT-PCR. 1-2 days after transfection, increased CTGF expression was detected, but no induction of TGFb3, MMP13, or THBS2 was observed (Figure 6a and data not shown). In contrast, CTGF overexpression upregulated OPN.
Two days after transfection, cells were transferred to serum-free medium to assess their ability to survive. After 10 days without serum, non-transfected cells were eliminated, whereas transfected cells survived showing that CTGF expression promotes serum independence (Figure 6c) . Nevertheless, these cells show the same regular round morphology as the untransfected cells in 10% serum, differing from the elongated morphology of the taf4 À/À cells and T-RA-treated taf4 lox/À cells. Thus, although CTGF over-expression can promote survival it does not induce the morphological changes seen upon loss of TAF4 or T-RA treatment.
We verified expression of several target genes in the transfected cells cultured for 10 days without serum. As observed in the transient expression assays in 10% serum, the cells in 0% serum showed elevated OPN expression, In addition, MMP13 and VAV3 were upregulated in 0% serum, while GAS2 was repressed, but there was no significant induction of TGFb1 and b3 or THBS2 (Figure 6b and data not shown). This confirms that CTGF overexpression only partially recapitulates the phenotype seen upon loss of TAF4 or T-RA treatment. Clearly, the induction or repression of other genes is required to elicit the full spectrum of changes.
T-RA-regulated loci
We noted that the CTGF gene resides in an evolutionary conserved locus close to ENPP1 and ENPP3 on chromosome 10 band A3 (Supplementary Figure 4A) . This organization is conserved on human chromosome 6, and even in more distantly related species such as Xenopus tropicalis. The gene encoding the mediator 
RA-TGF-b crosstalk
A Fadloun et al subunit MED23 (CRSP3) required for ELK-1 function is also located at this locus and is upregulated by T-RA (Figure 3a) . These genes belong therefore to an evolutionary conserved T-RA-regulated locus. Nevertheless, in contrast to CTGF, the proximal promoter regions of these genes were not well conserved and no obvious RAREs could be detected (with the exception of a potential DR2-type RARE in the MED23 promoter, Supplementary Figure 7) . The RAREs could therefore be located at distal upstream or downstream elements within this locus.
We also examined the regulatory regions of other rapidly induced genes and identified a potential DR2 type RARE in the first intron of the MBD1 gene ( Supplementary Figures 5 and 7) . Oligonucleotides with this element were used in EMSA forming a retarded complex with the same mobility as the CRABP2 RARE (Figures 5a and c, lanes 7 and 15 compared with lanes 1,  5 and 10) . Formation of the retarded complex was competed by homologous cold MBD1 oligonucleotide (lane 9) and also by cold CRABP2 DNA (lane 16). This element therefore efficiently binds the RAR/RXR heterodimer and may contribute to T-RA regulation of MBD1.
In addition to the RAR/RXR heterodimer complex, a second faster migrating complex was observed. The MBD1 RARE overlaps with two potential GAGA binding motifs (5 0 -GAGAA-3 0 and 5 0 -GAGAG-3, Figure 5a ). A mutation in the 5 0 repeat of the DR2, that does not affect the GAGA motifs results in strongly diminished formation of the RAR/RXR complex, but does not affect the faster migrating complex (Figure 5c , lanes 7-8). Similarly, both complexes are competed by the MBD1 oligonucleotide, but only the RAR/RXR complex is competed by the heterologous CRAPB2 DNA (lanes 9 and 16). The MBD1 oligonucleotide therefore binds both RAR/RXR and a second factor possibly the GAGA factor.
We further noted that several downregulated genes were clustered on chromosome 6 band A3 (Supplementary Figure 6 ). Among the most potently downregulated genes in taf4 lox/À cells are MEST (mesoderm specific 
A Fadloun et al transcript) and COPG2AS (co-atomer protein complex, subunit gamma 2, antisense, see Figure 2b and Supplementary Table 1) . MEST is transcribed in the opposite direction from COPG2 and their 3 0 -UTRs overlap. The COPG2AS2 transcript is poorly characterized, but originates within the MEST gene and runs into the COPG2 transcript (Lee et al., 2000) . Upstream of MEST is the TSGA14 (testis specific gene A14) that is transcribed in the opposite direction from MEST and is also downregulated by T-RA in taf4 lox/À cells (Figure 2b  and Supplementary Table 1 ).
These observations suggest that there may be an important control region(s) upstream of MEST that mediates T-RA regulation of the MEST, COPG2AS and the divergently transcribed TSGA14. We identified one potential DR5-type RARE at position -191 in the proximal promoter region upstream of MEST (Supplementary Figures 6 and 7, and Figure 5a ). EMSA experiments showed that oligonucleotides with this element formed a complex of the same mobility as that of the CRAPB2 element (Figure 5c lanes 3 and 12) . Formation of this complex could be competed by cold homologous oligonucleotides or by the CRABP2 and CTGF oligonucleotides (lanes 4, 13-14) . These observations suggest this element may be a potential RARE.
As GAS2 is rapidly downregulated by T-RA, we also examined its promoter for RAREs. A potential DR1 element located at À280 in the proximal promoter was observed (Figure 5a and Supplementary Figure 7) . This element also specifically bound the RAR/RXR in EMSA experiments (Figure 5c lanes 17-18) .
Discussion
TAF4 is a cofactor for the T-RA-regulated gene expression programme in fibroblasts We have characterized the T-RA response of mouse embryonic fibroblasts in the presence or absence of TAF4. In normal TAF4-expressing cells, T-RA induces morphological change and deregulates the expression of almost 1000 genes, whereas in TAF4 mutant cells, a significantly diminished response is observed where less than 300 genes are affected. Some genes are induced irrespective of the presence or absence of TAF4, among which are known direct target genes, such as RARb2, DHRS3 a short-chain dehydrogenase/reductase thought to regenerate retinol from retinal and to be involved in generating storage forms of retinol (Cerignoli et al., 2002) , NID1 (nidogen 1/entactin), or TGM2 (transglutaminase 2, C polypeptide) (Krig et al., 2002) or potential novel target genes, such as INMT, rapidly induced by T-RA.
In contrast, a large number of genes are induced only in the TAF4-expressing cells. These can be divided into two classes, those also regulated by loss of TAF4 and involved in TGFb signalling (see below) and a group of 270 genes that are uniquely induced by T-RA in the TAF4-expressing cells. Many of these, such as MBD1 are rapidly and potently induced and may be a direct target. The presence of a DR2 element in the first intron of MBD1 that binds RAR/RXR heterodimers further supports this idea. MBD1 may also be involved in subsequent RAR-mediated repression (Villa et al., 2006) , while another potently induced gene HMGA1, interacts with RAR and acts as a positive cofactor (Nagpal et al., 1999) . Similarly, we find a rapid and potent induction of ENPP1 suggesting it is also a direct target gene. ENPP1/PC-1 has been implicated in type 2 diabetes (Meyre et al., 2005) acting as an insulin receptor antagonist (Maddux et al., 1995) in fibroblasts and muscle. The observation that it is a potential RAR target gene provides a novel link between T-RA signalling and insulin resistance. It remains to be determined which other genes of this class are primary targets for the RARs.
Few genes are downregulated irrespective of the presence of TAF4, but most are repressed by T-RA only in the taf4 lox/À cells. Evaluating the kinetics of downregulation is more complex due to differences in the half-lives of the mRNAs. However, we show that GAS2 may be a direct target gene as its downregulation is rapid and that its promoter contains a potential DR1 element associated with repression (reviewed in (Bastien and Rochette-Egly, 2004 ) that binds RAR/RXR in vitro. It has been proposed that GAS2 expression increases p53-dependent apoptosis (Benetti et al., 2001) . Repression of GAS2 expression by T-RA may therefore MEST may also be a directly repressed target as its proximal promoter contains a DR5 RARE that binds RAR/RXR in vitro. Unlike the GAS2 promoter, this RARE is a DR5 element classically associated with T-RA-dependent activation. In the case of MEST, we find a non-canonical DR5 element associated with a gene that is potently repressed by T-RA. Promoter context effects may therefore modulate the potential of the RAR/RXR heterodimer to activate or repress transcription.
Comparison of T-RA-regulated genes in fibroblasts with those regulated during parietal endoderm differentiation of F9 embryonal carcinoma cells Eifert et al., 2006) or neuronal differentiation of P19 cells (Wei et al., 2002) reveals only a limited number of common targets and in some cases, T-RA even has an opposite effect as TEF (thyrotroph embryonic factor) is induced during F9 differentiation, but repressed in fibroblasts. Otherwise, the repertoire of T-RA-regulated genes in F9/P19 cells and fibroblasts is distinct. Induction of CTGF has been observed in T-RA-induced neuronal differentiation of human NT2/ D1 cells (Freemantle et al., 2002) . However, T-RA induces growth arrest and differentiation of these cells, a situation very different from that seen with fibroblasts.
A genetic blueprint for T-RA/TGFb cross talk While many previous studies have associated T-RA with arrest of cell cycle and/or differentiation, an important observation in this study is that T-RA induces the growth promoting TGFb pathway in fibroblasts. It is interesting to note that a transient 24 h T-RA treatment is sufficient to induce self-sustaining autocrine TGFb signalling. While it is not yet clear whether T-RA directly induces TGFb expression, we have identified CTGF as a direct RAR target gene through a conserved DR2 RARE in its proximal promoter. Evaluating RAR binding in vivo is hampered by the lack of anti-RAR antibodies for chromatin immunoprecipitation. However, the presence of this RARE and the rapid induction kinetics indicate that it is a direct target gene. Interestingly, the DR2 element overlaps with an element reported to be involved in TGFb-induction of CTGF expression (Grotendorst et al., 1996) . As direct interactions between the RARg and SMAD3 have been described (Pendaries et al., 2003) , it is possible that the SMADs bind to this sequence via the RARg. Nevertheless, a second element binding TEAD/TEF factors (TGFbRE, in Supplementary Figure 4B ) required for TGFb-induction has also been reported . Furthermore, as previously described for TGFb (Grotendorst et al., 1996) , CTGF is induced by T-RA only in fibroblasts and not in HeLa and Cos cells. Further dissection of this promoter will be required to fully understand its complex regulation.
The potent and rapid T-RA-induction of CTGF induces serum independence and regulates expression of several other genes of the pathway. In contrast, the characteristic morphological change is not observed and TGFb expression is not induced. Hence, T-RA activation or repression of other genes must be required to elicit the full response and further experiments will unravel the complex networks underlying the T-RA response and TGFb-signalling.
T-RA deregulates the TGFb signalling pathway leading to autocrine growth, a phenotype analogous to that of taf4 À/À cells. Comparison of genes regulated by T-RA in taf4 lox/À cells and by loss of TAF4 reveals a common set of 119 induced, and 259 repressed genes associated with this phenotype. Their analogous regulation identifies a genetic blueprint for TGFb-mediated autocrine growth. For many, there is an obvious correlation with the deregulated TGFb phenotype. For example, factors involved in promoting TGFb signalling, TGFb1 and TGFb3, CTGF (Brigstock, 2003; and the TGFb receptor 3 are induced along with activators of latent TGFb such as THBS1 and 2, (Yu and Stamenkovic, 2000; Annes et al., 2003) and transcription factors associated with growth. In contrast, the TGFb antagonist ASPN or the proapoptotic gene GAS2 is strongly downregulated. In addition, this group includes a series of genes shown to be involved in adaptation of fibroblasts to growth in low serum (Mengus et al., 2005) . Together, these observations define a genetic programme that promotes morphological change and TGFb-dependent autocrine growth in fibroblasts.
Cross talk between the T-RA and TGFb pathways has been previously observed (Roberts and Sporn, 1992) . For example, T-RA induces TGFb2 in cultured keratinocytes and mouse epidermis (Glick et al., 1989) . T-RA stimulation of TGFb2 expression in epidermis and various other tissues in vivo in vitamin A-deficient rats has also been observed (Glick et al., 1991) . In these animals, a complex tissue-specific activation or repression of the three TGFb genes was observed. Similarly, T-RA increases expression of TGFb1 and the TGFb receptor in HL60 cells leading to an autocrine antiproliferative growth loop (Falk et al., 1991; Nunes et al., 1996) . However, it has been shown that T-RA reduces SMAD phosphorylation in HL60 cells, thus negatively regulating TGFb-signalling and differentiation into monocytes (Cao et al., 2003) . T-RA has also been shown to regulate TGFb expression and proliferation in embryonic palate mesenchymal cells (Nugent et al., 1998) and more recently, to regulate TGFb in the embryonal yolk sac to ensure visceral endoderm survival (Bohnsack et al., 2004) . Together with our present results, these observations shown that T-RATGFb cross talk occurs in a variety of tissues and can have distinct functional consequences depending on the cell type.
In most of the above examples, T-RA-stimulated TGFb expression acts to restrict cell proliferation. In contrast, T-RA stimulates TGFb production from liver stellate cells and exacerbates fibrosis (Koda et al., 1996; Okuno et al., 1997 Okuno et al., , 2002 . This is consistent with the fact that TGFb promotes proliferation of mesenchymal cells, but inhibits growth of epidermal and haematopoietic cells. While the above studies highlight the consequences of T-RA-TGFb cross talk in vivo, they did not address in detail the molecular mechanisms involved. Our study provides a much more complete description of the functional cross talk between these two pathways helping to better understand the molecular mechanism of action of T-RA in normal and pathological contexts.
Materials and methods
Culture of embryonic fibroblasts
The taf4 lox/À and taf4 À/À embryonic fibroblasts were grown in Dulbecco's minimal essential media supplemented with glutamax and with or without 10% fetal calf serum as indicated. 10 À6 M T-RA was added to the cultures for the times indicated. Recombinant TGFb1 is from Sigma and SB431542 from TOCRIS.
Affymetrix gene profiling and data analysis Duplicate independent preparations of total RNA from both of the taf4 lox/À and taf4 À/À clones exponentially growing in 10% serum in the presence or absence of T-RA (total of 16) were analysed on the Mouse Genome GeneChip 430A 2.0, comprising 22 600 probe sets representing over 14 500 mouse genes. Profiling and statistical analysis were performed as described in ((Mengus et al., 2005) and see Supplementary materials).
RT-PCR and immunoblots
For RT-PCR, 1 mg of RNA from the cells treated as described in each figure was reverse transcribed with the SuperscriptII system (Invitrogen, Carlsbad, CA, USA) using hexanucleotide primers in a volume of 20 ml. 1 ml of a 1/10 dilution was used for PCR. Fragments between 150 and 200 bp were amplified.
The sequences of the oligonucleotide primers for each gene are available upon request. Q-PCR was performed using a Roche light cycler and the cyber green kit (Qiagen, Valencia, CA, USA). Phosphorylated SMAD2/3 was detected using antibody (3101) from Cell Signalling, Danvers, MA, USA.
Transfection and EMSA Cos-1 cells were transfected with 4 mg of the RARg and RXRa expression vectors using Jet-PEI (Polyplus transfection). After 48 h, cell extracts were prepared and EMSA performed essentially as previously described (Jacquemin et al., 1996) . For CTGF overexpression, taf4 lox/À cells were transfected with 4 mg of the CTGF expression vector (or empty pXJ40 as control). After 48 h, RNA was prepared or cells were transferred to serum-free media for 5 days before acquiring images or RNA preparation. The CTGF expression vector was constructed by PCR amplification of the full-length cDNA from taf4 À/À cell RNA using oligonucleotide primers with EcoRI and BglII restriction sites and cloned into the corresponding sites of the pXJ40 expression vector.
